Pharmaceutical compositions comprising Fatty Acid Fumarate Derivatives, and methods of using Fatty Acid Fumarate Derivatives and pharmaceutical compositions thereof for treating heart failure diseases, including heart failure with preserved ejection fraction (HFPEF), comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
